

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-A**

---

**For Registration of Certain Classes of Securities  
Pursuant to Section 12(b) or (g) of  
the Securities Exchange Act of 1934**

---

**Foghorn Therapeutics Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**47-5271393**  
(I.R.S. Employer Identification No.)

**500 Technology Square, Ste 700  
Cambridge MA 02139  
United States**  
(Address of principal executive offices)

**02139**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

Title of each class  
to be so registered  
**Common Stock, \$0.0001 par value**

Name of each exchange on which  
each class is to be registered  
**The Nasdaq Stock Market LLC**

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

**Securities Act registration statement or Regulation A offering statement file number to which this form relates (if applicable):**  
**333-249264**

**Securities to be registered pursuant to Section 12(g) of the Act:**  
**None**

---

---

---

**Item 1. Description of Registrant's Securities to be Registered.**

Foghorn Therapeutics Inc. (the "Registrant") hereby incorporates by reference the description of its common stock, \$0.0001 par value per share (the "Common Stock"), to be registered hereunder, contained under the heading "Description of capital stock—Common Stock" in the Registrant's registration statement on Form S-1 (File No. 333-249264) (the "Registration Statement") filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Act"). Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Act that constitutes part of the Registration Statement shall also be deemed to be incorporated herein by reference.

**Item 2. Exhibits.**

Pursuant to the Instructions as to exhibits with respect to Form 8-A, no exhibits are filed herewith or incorporated herein by reference because no securities of the Registrant other than the Common Stock are registered on the The Nasdaq Stock Market and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: October 19, 2020

**FOGHORN THERAPEUTICS INC.**

By: /s/ Adrian Gottschalk

Name: Adrian Gottschalk

Title: Chief Executive Officer